[Home]  [About us]  [Diseases ]   [Research]   [Products]   [MICROS]   [Clinical]   [Collaboration]   [Contact]

Innovative treatment for unmet needs in neurological diseases

Neurons Brain Neurons Brain biochemicals MICROS Infusion System Human brain signals Alzheimer patient Famous People with Alzheimer

Bioneuromed Corporation

Bioneuromed, LLC (which has been changed to NeuroActiva, Inc.) is a bio-pharmaceutical company committed to the discovery and development of new drugs to treat neurological diseases for which there is significant unmet medical need.

Read More

ABOUT US

Bioneuromed's products are designed to support the regeneration of neuronal cells and tissue with its ability to repair damage caused by disease, trauma or age.

DISEASES

Bioneuromed focuses on unmet medical needs: Alzheimer's disease, Parkinson's disease, Edema, Multiple Sclerosis , traumatic brain injury, stroke, and brain cancer.

RESEARCH

Our core research areas focuses on Alzheimer's disease and Multiple Sclerosis. We will conduct research on Parkinson's disease, traumatic brain injury, stroke, and brain cancer.

CLINICAL

NA-831 can stimulate regeneration of neurons, outgrowth of electrically active fibres, restoration of neuronal function. We plan to conduct the Phase 1 Clinical Trial by the end of 2017.

.

PRODUCTS

Na-831 (Traneurocin) is a novel neuroprotective and neurogensis drug candidate for the treatment of Alzheimer's disease and other neurologic disorders.

MICROS Infuser

The MICROS is a FDA approved intravenous drug delivery system for injectable drugs, including NA-831 for treatment of neurological diseases in homecare settings.

Bioneuromed focuses on developing of treatment of Alzheimer's disease:

  • Alzheimer's disease

    Alzheimer's Disease

    Alzheimer's disease is the only cause of death in the top 10 in America that cannot be prevented, cured or slowed. Alzheimer is the 6th leading cause of death in the USA.

  • Research

    Research

    Bioneuromed research focuses on the neuroprotection and regeneration of cells and tissue with its ability to repair damage caused by disease, trauma or age.

  • Clinical

    Clinical

    NA-831 is a novel neuroprotective drug, which is already in existance in the brain, with excellent safety profile. We plan to conduct the Phase 1 Safety Study by the end of 2017

  • NA-831

    NA-831

    NA-831 stimulates regeneration of neurons, outgrowth of electrically active fibres, restoration of neuronal function, a major clinical feature of both Alzheimer's disease.

  • MICROS Infusion System

    MICROS Infusion System

    The MICROS is a FDA approved disposable infusion system for intravenous administration of injectable drugs, including NA-831 for treatment of neurological diseases.